CD4+ T lymphocytes: A critical component of antitumor immunity

  • Ostrand-Rosenberg S
  • 9

    Readers

    Mendeley users who have this article in their library.
  • 68

    Citations

    Citations of this article.

Abstract

Both prophylactic and therapeutic vaccines targeting a wide variety of cancers are being developed. Because of the potency of cell-mediated immunity, many vaccine strategies are focused on activating tumor-specific cytotoxic CD8+ T lymphocytes. CD4+ T lymphocytes are a key element in optimal activation of CD8+ T cells and in the maintenance of immune memory, and therefore their activation is critical for cancer vaccine efficacy. This article reviews the mechanisms by which CD4+ T cells facilitate tumor immunity and the vaccine strategies that enhance CD4+ T cell activity.

Author-supplied keywords

  • CD4+T lymphocytes
  • MHC class II
  • Tumor-specific immunity

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Suzanne Ostrand-Rosenberg

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free